Skip to content

Alkermes ALKS Inventories

Inventories at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.76B+3.4%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$437.5M-11.2%
AbbVie logo
AbbVieABBV
$5.05B+11.6%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$31.52M+93.1%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$5.56M-51.7%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM

Other financials

Income statement

See full
Revenue$392.9M+28.2%
Gross profit$331.3M+28.8%
Operating income-$48.3M-450%
Net income-$66.5M-396%
EPS (diluted)-$0.40-408%

Balance sheet

See full
Cash & equivalents$351.6M-12.1%
Total debt$1.6B+2,034%
Total equity$1.8B+15.9%
Total assets$4.3B+105%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$4.1M-59.5%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$7.5B+9.7%
Enterprise value$8.73B+41.2%
P/E49.1×+29.7×
P/S4.8×+0.3×

Profitability

See full
Gross margin86.6%+2.2pp
Operating margin12.3%-13.6pp
Net margin9.8%-13.5pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity9.4%-16.1pp
Debt / equity0.9×+0.9×
Current ratio2.3×-1.1×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:InventoryNet.

The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alkermes's inventories?
Alkermes (ALKS) reported inventories of $336.7M in Q1 2026.
How has Alkermes's inventories changed year-over-year?
Alkermes's inventories increased by 83.6% year-over-year, from $183.44M to $336.7M.
What is the long-term trend for Alkermes's inventories?
Over 5 years (2020 to 2025), Alkermes's inventories has grown at a 9.4% compound annual growth rate (CAGR), from $125.74M to $196.63M.
What does inventories mean?
Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.